Industry Verticals »

All Categories

Insights »

About TMR »

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market (Therapeutics and Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of cystic fibrosis and chronic pancreatitis to escalate the growth of global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Moreover, rising cases of diabetes are expected to fuel growth of the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
  • According to the report, the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market was valued at US$ 3.9 Bn in 2018 and is anticipated to expand at a CAGR of 7.2% from 2019 to 2027
new fa global exocrine pancreatic insufficiency

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

  • EPI is caused by insufficient secretion of pancreatic enzymes such as amylase, lipase, and protease and/ or sodium bicarbonate. Several disorders including different types of diabetes are associated with significantly increased risk for exocrine pancreatic insufficiency (EPI). For instance, according to an article published in Current Diabetes Reports, states that the prevalence of exocrine pancreatic insufficiency (EPI) is higher in type 1 diabetes than in type 2 diabetes. Thus, surge in number of people with diabetes is a key factor anticipated to drive the growth of exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
  • Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030
  • This is augmenting the demand for new treatment. To address these demands, the key players are investing in the research and development activities to develop and introduce new exocrine pancreatic insufficiency therapeutics thereby boosting the growth of market. For instance, AzurRx is developing a yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments

Increase in Prevalence of Chronic Pancreatitis and Cystic Fibrosis Propel Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Growth

  • Cystic fibrosis is the most common cause of exocrine pancreatic insufficiency. Around 50% of infants with cystic fibrosis have exocrine pancreatic insufficiency at birth, and another 25% develop it within six months. An additional 15% develop exocrine pancreatic insufficiency sometime in childhood or early adulthood.
  • Thus, rise in the global incidence of cystic fibrosis and chronic pancreatitis is one of the major factors driving the exocrine pancreatic insufficiency therapeutics & diagnostics market

Stringent FDA Regulations to Hamper Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

  • Pancreatic enzyme replacement therapy (PERT) using pancrelipase products, which are mostly purified from the porcine pancreas, has been tested widely for exocrine pancreatic insufficiency associated with pancreatic diseases. Pancreatic enzyme products have been available as over-the-counter drugs in many regions for several years.
  • However, some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is leading to restrain the growth of market

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Competitive Landscape

  • This report profiles major players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global exocrine pancreatic insufficiency therapeutics & diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market
    • AbbVie, Inc
    • Allergan plc.
    • Nordmark Arzneimittel GmbH & Co. KG
    • Digestive Care, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Cilian AG
    •  Anthera Pharmaceuticals, Inc
    • AzurRx Biopharma, Inc.

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Key Developments

Key players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global exocrine pancreatic insufficiency therapeutics & diagnostics market. A few expansion strategies adopted by players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are:

  • In April 2020, AzurRx Biopharma, Inc. has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)
  • In April 2020, AzurRx Biopharma, Inc. has entered into a manufacturing agreement with Delpharm for the clinical drug product supply of its MS1819 therapy for exocrine pancreatic insufficiency (EPI)
  • In February 2020, Vivus Inc. announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for PANCREAZE. PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions

The report on the global exocrine pancreatic insufficiency therapeutics & diagnostics market discussed individual strategies, followed by company profiles of manufacturers of exocrine pancreatic insufficiency therapeutics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market.

Frequently Asked Questions

What is the total market worth of exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market?

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market to reach US$ 7.3 Bn by 2027

What is the anticipated CAGR of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the forecast period?

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is anticipated to expand at a CAGR of 7.2% from 2019 to 2027

What are the key driving factors for the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market?

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is driven by rising cases of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis

Which region is expected to project the highest market share in the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market?

North America accounted for a major share of the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market

Who are the key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market?

Key players in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market include AbbVie, Inc., Allergan plc, Nordmark Arzneimittel GmbH & Co. KG, Digestive Care, Inc., Janssen Pharmaceuticals, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Type/Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, 2017–2027

    5. Key Insights

        5.1. Brand Analysis

        5.2. Pipeline Analysis

        5.3. Key Industry Events 

    6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast By Type, 2017–2027

            6.3.1. Therapeutics

            6.3.2. Diagnostics

                6.3.2.1. Blood Tests

                6.3.2.2. Endoscopic Ultra-sonography (EUS)

                6.3.2.3. Magnetic Resonance Imaging (MRI)

                6.3.2.4. CT Scanning

        6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness by Type

    7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, by Region

        7.1. Key Findings

        7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Region

            7.2.1. North America 

            7.2.2. Europe 

            7.2.3. Asia Pacific 

            7.2.4. Latin America 

            7.2.5. Middle East & Africa 

        7.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness by Country/Region

    8. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Type, 2017–2027

            8.2.1. Therapeutics

            8.2.2. Diagnostics

                8.2.2.1. Blood Tests

                8.2.2.2. Endoscopic Ultra-sonography (EUS)

                8.2.2.3. Magnetic Resonance Imaging (MRI)

                8.2.2.4. CT Scanning

        8.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Country, 2017–2027

            8.3.1. U.S.

            8.3.2. Canada

        8.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness Analysis 

            8.4.1. By Type

            8.4.2. By Country

    9. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Type, 2017–2027

            9.2.1. Therapeutics

            9.2.2. Diagnostics

                9.2.2.1. Blood Tests

                9.2.2.2. Endoscopic Ultra-sonography (EUS)

                9.2.2.3. Magnetic Resonance Imaging (MRI)

                9.2.2.4. CT Scanning

        9.3. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Country/Sub-region, 2017–2027

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Spain

            9.3.5. Italy

            9.3.6. Rest of Europe

        9.4. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness Analysis 

            9.4.1. By Type

            9.4.2. By Country/Sub-region

    10. Asia Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Asia Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Type, 2017–2027

            10.2.1. Therapeutics

            10.2.2. Diagnostics

                10.2.2.1. Blood Tests

                10.2.2.2. Endoscopic Ultra-sonography (EUS)

                10.2.2.3. Magnetic Resonance Imaging (MRI)

                10.2.2.4. CT Scanning

        10.3. Asia Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Country/Sub-region, 2017–2027

            10.3.1. China

            10.3.2. Japan

            10.3.3. India

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Asia Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness Analysis 

            10.4.1. By Type

            10.4.2. By Country/Sub-region

    11. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Type, 2017–2027

            11.2.1. Therapeutics

            11.2.2. Diagnostics

                11.2.2.1. Blood Tests

                11.2.2.2. Endoscopic Ultra-sonography (EUS)

                11.2.2.3. Magnetic Resonance Imaging (MRI)

                11.2.2.4. CT Scanning

        11.3. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Country/Sub-region, 2017–2027

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness Analysis 

            11.4.1. By Type

            11.4.2. By Country/Sub-region

    12. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Type, 2017–2027

            12.2.1. Therapeutics

            12.2.2. Diagnostics

                12.2.2.1. Blood Tests

                12.2.2.2. Endoscopic Ultra-sonography (EUS)

                12.2.2.3. Magnetic Resonance Imaging (MRI)

                12.2.2.4. CT Scanning

        12.3. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Country/Sub-region, 2017–2027

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness Analysis 

            12.4.1. By Type

            12.4.2. By Country/Sub-region

    13. Competition Landscape

        13.1. Market Player – Competition Matrix (By Tier and Size of companies)

        13.2. Market Share Analysis/Ranking by Company (2018)

        13.3. Company Profiles

            13.3.1. AbbVie, Inc.

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Growth Strategies

                13.3.1.3. SWOT Analysis. 

            13.3.2. Allergan plc

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Growth Strategies

                13.3.2.3. SWOT Analysis. 

            13.3.3. Nordmark Arzneimittel GmbH & Co. KG

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Growth Strategies

                13.3.3.3. SWOT Analysis. 

            13.3.4. Digestive Care, Inc.

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Growth Strategies

                13.3.4.3. SWOT Analysis. 

            13.3.5. Janssen Pharmaceuticals, Inc.

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Growth Strategies

                13.3.5.3. SWOT Analysis. 

            13.3.6. Cilian AG

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Growth Strategies

                13.3.6.3. SWOT Analysis. 

            13.3.7. Anthera Pharmaceuticals, Inc.

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Growth Strategies

                13.3.7.3. SWOT Analysis. 

            13.3.8. AzurRx Biopharma, Inc.

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Growth Strategies

                13.3.8.3. SWOT Analysis. 

    List of Table

    Table 01: Global EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 02: Global EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Table 03: Global EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 04: Global EPI Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 05: Global EPI Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 06: North America EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 07: North America EPI Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 08: North America EPI Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 09: North America EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 10: North America EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Table 11: Europe EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 12: Europe EPI Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 13: Europe EPI Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 14: Europe EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 15: Europe EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Table 16: Asia Pacific EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 17: Asia Pacific EPI Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 18: Asia Pacific EPI Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 19: Asia Pacific EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 20: Asia Pacific EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Table 21: Latin America EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 22: Latin America EPI Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 23: Latin America EPI Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 24: Latin America EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 25: Latin America EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Table 26: Middle East & Africa EPI Therapeutics & Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 27: Middle East & Africa EPI Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 28: Middle East & Africa EPI Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 29: Middle East & Africa EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Type, 2017–2027

    Table 30: Middle East & Africa EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast, by Diagnostics, 2017–2027

    List of Figure

    Figure 01: Global EPI Therapeutics & Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 02: Global EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 03: Global EPI Therapeutics & Diagnostics Market Attractiveness Analysis, by Type, 2019–2027

    Figure 04: Global EPI Therapeutics & Diagnostics Market Value Share, by Diagnostics, 2018 and 2027

    Figure 05: Global EPI Therapeutics & Diagnostics Market Attractiveness, by Diagnostics, 2019–2027

    Figure 06: Global Exocrine Pancreatic Insufficiency Market Revenue (US$ Mn) Forecast, by Therapeutics, 2017–2027

    Figure 07: Global Exocrine Pancreatic Insufficiency Market Revenue (US$ Mn) Forecast, by Diagnostics, 2017–2027

    Figure 08: Global Exocrine Pancreatic Insufficiency Diagnostics Market Revenue (US$ Mn) Forecast, by Blood Tests, 2017–2027

    Figure 09: Global Exocrine Pancreatic Insufficiency Diagnostics Market Revenue (US$ Mn) Forecast, by Endoscopic Ultra- sonography (EUS), 2017–2027

    Figure 10: Global Exocrine Pancreatic Insufficiency Diagnostics Market Revenue (US$ Mn) Forecast, by Magnetic Resonance Imaging (MRI), 2017–2027

    Figure 11: Global Exocrine Pancreatic Insufficiency Diagnostics Market Revenue (US$ Mn) Forecast, by CT Scanning, 2017–2027

    Figure 12: Global EPI Therapeutics & Diagnostics Market Value Share, by Region, 2018 and 2027

    Figure 13: Global EPI Therapeutics & Diagnostics Market Attractiveness, by Region, 2019–2027

    Figure 14: North America EPI Therapeutics & Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 15: North America EPI Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 16: North America EPI Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 17: North America EPI Therapeutics & Diagnostics Market Value Share, by Country, 2018 and 2027

    Figure 18: North America EPI Therapeutics & Diagnostics Market Attractiveness, by Country, 2019–2027

    Figure 19: North America EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 20: North America EPI Therapeutics & Diagnostics Market Attractiveness, by Type, 2019–2027

    Figure 21: Europe EPI Therapeutics & Diagnostics Market Value (US$ Mn), 2017–2027

    Figure 22: Europe EPI Therapeutics Market Value (US$ Mn), 2017–2027

    Figure 23: Europe EPI Diagnostics Market Value (US$ Mn), 2017–2027

    Figure 24: Europe EPI Therapeutics & Diagnostics Market Value Share, by Country, 2018 and 2027

    Figure 25: Europe EPI Therapeutics & Diagnostics Market Attractiveness, by Country, 2019–2027

    Figure 26: Europe EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 27: Europe EPI Therapeutics & Diagnostics Market Attractiveness, by Type, 2019–2027

    Figure 28: Asia Pacific EPI Therapeutics & Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 29: Asia Pacific EPI Therapeutics & Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), by Therapeutics, 2017–2027

    Figure 30: Asia Pacific EPI Therapeutics & Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), by Diagnostics, 2017–2027

    Figure 31: Asia Pacific EPI Therapeutics & Diagnostics Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 32: Asia Pacific EPI Therapeutics & Diagnostics Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 33: Asia Pacific EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 34: Asia Pacific EPI Therapeutics & Diagnostics Market Attractiveness, by Type, 2019–2027

    Figure 35: Latin America EPI Therapeutics & Diagnostics Market Value (US$ Mn), 2017–2027

    Figure 36: Latin America EPI Therapeutics Market Value (US$ Mn), 2017–2027

    Figure 37: Latin America EPI Diagnostics Market Value (US$ Mn), 2017–2027

    Figure 38: Latin America EPI Therapeutics & Diagnostics Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 39: Latin America EPI Therapeutics & Diagnostics Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 40: Latin America EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 41: Latin America EPI Therapeutics & Diagnostics Market Attractiveness, by Type, 2019–2027

    Figure 42: Middle East & Africa EPI Therapeutics & Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 43: Middle East & Africa EPI Therapeutics & Diagnostics Market Value (US$ Mn), by Therapeutics, 2017–2027

    Figure 44: Middle East & Africa EPI Therapeutics & Diagnostics Market Value (US$ Mn), by Diagnostics, 2017–2027

    Figure 45: Middle East & Africa EPI Therapeutics & Diagnostics Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 46: Middle East & Africa EPI Therapeutics & Diagnostics Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 47: Middle East & Africa EPI Therapeutics & Diagnostics Market Value Share, by Type, 2018 and 2027

    Figure 48: Middle East & Africa EPI Therapeutics & Diagnostics Market Attractiveness, by Type, 2019–2027

    Figure 49: Global EPI Therapeutics Market Share, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

Schedule a Call